# Edoxaban for Prevention of Blood Vessels Being Blocked by Clots (Thrombotic Events) in Children at Risk Because of Cardiac Disease

> **NCT03395639** · PHASE3 · COMPLETED · sponsor: **Daiichi Sankyo** · enrollment: 168 (actual)

## Conditions studied

- Cardiac Disease

## Interventions

- **DRUG:** Edoxaban
- **DRUG:** Standard of Care (SOC)

## Key facts

- **NCT ID:** NCT03395639
- **Lead sponsor:** Daiichi Sankyo
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-05-15
- **Primary completion:** 2021-12-03
- **Final completion:** 2021-12-03
- **Target enrollment:** 168 (ACTUAL)
- **Last updated:** 2022-07-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03395639

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03395639, "Edoxaban for Prevention of Blood Vessels Being Blocked by Clots (Thrombotic Events) in Children at Risk Because of Cardiac Disease". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT03395639. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*